Ranbaxy Records $568 Million Loss For DoJ Penalty; Sees More Predictability In U.S. Business
This article was originally published in The Pink Sheet Daily
India’s Ranbaxy has reported mixed results as it tops $2 billion in sales but suffers $568 million in losses from a U.S. consent decree penalty.
You may also be interested in...
MUMBAI - For Ranbaxy Laboratories Ltd., it has been nearly a decade-long bumpy ride to discover and develop its anti-malarial compound, but India's regulator - the Drug Controller General of India - finally granted the company a conditional approval to market the compound
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.